<div><b>References</b></div><ol><li>Xiang H, Xue Y, Chen Z, et al. The association between left
ventricular hypertrophy and the occurrence and prognosis of atrial
fibrillation: A meta-analysis. Front Cardiovasc Med 2021;8: 639993.
doi: 10.3389/fcvm.2021.639993</li><li>Haider AW, Larson MG, Benjamin EJ, Levy D. Increased left ventricular
mass and hypertrophy are associated with increased risk of sudden
death. J Am Coll Cardiol 1998;32(5): 1454-1459.</li><li>Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for
the management of patients with atrial fibrillation executive summary:
a report of the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines and the European Society
of Cardiology Committee for Practice Guidelines (Writing Committee to
Revise the 2001 Guidelines for the Management of Patients with Atrial
Fibrillation) developed in collaboration with the European Heart
Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol.
2006;48: 854-906.</li><li>Aronson RS. Mechanisms of arrhythmias in ventricular hypertrophy. J
Cardiovasc Electrophysiol 1991;2: 249-261.</li><li>Ben-David J, Zipes DP, Ayers GM, Pride HP. Canine left ventricular
hypertrophy predisposes to ventricular tachycardia induction by phase
2 early afterdepolarizations after administration of BAY K 8644. J Am
Coll Cardiol 1992;20: 1576-1584.</li><li>Yan GX, Rials SJ, Wu Y, Liu T, Xu X, Marinchak RA, Kowey PR.
Ventricular hypertrophy amplifies transmural repolarization dispersion
and induces early afterdepolarization. Am J Physiol Heart Circ Physiol
2001;281: H1968-H1975.</li><li>Gillis AM, Mathison HJ, Kulisz E, Lester WM. Dispersion of ventricular
repolarization in left ventricular hypertrophy: influence of afterload
and dofetilide. J Cardiovasc Electrophysiol 1998;9(9): 988-997.</li><li>Kowey PR, Friehling TD, Sewter J, Wu Y, Sokil A, Paul J, Nocella J.
Electrophysiological effects of left ventricular hypertrophy. Effect
of calcium and potassium channel blockade. Circulation 1991;83:
2067-2075.</li><li>Wann DG, Medoff BS, Mehdi NA, et al. Dofetilide use is not associated
with increased mortality in patients with left ventricular hypertrophy
and atrial fibrillation. J Cardiovasc Electrophysiol 2022; In Press.
(This volume of JCE)</li><li>Abraham JM, Saliba WI, Vekstein C, et al. Safety of oral dofetilide
for rhythm control of atrial fibrillation and atrial flutter. Circ
Arrhythm Electrophysiol 2015;8: 772-776.</li><li>January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC,
Ellinor PT, Ezekowitz MD, Field ME, Furie KL, Heidenreich PA, Murray
KT, Shea JB, Tracy CM, Yancy CW. 2019 AHA/ACC/HRS Focused Update of
the 2014 AHA/ACC/HRS Guideline for the Management of Patients With
Atrial Fibrillation: A Report of the American College of
Cardiology/American Heart Association Task Force on Clinical Practice
Guidelines and the Heart Rhythm Society in Collaboration With the
Society of Thoracic Surgeons. Circulation 2019;140(2): e125-e151.</li><li>Chung R, Houghtaling PL, Tchou M, Niebauer MJ, Lindsay BD, Tchou PJ,
Chung MK. Left ventricular hypertrophy and antiarrhythmic drugs in
atrial fibrillation: Impact on mortality. Pacing Clin Electrophysiol
2014;37(10):1338-1348.</li><li>Barbieri A, Albini A, Maisano A, et al. Clinical value of complex
echocardiographic left ventricular hypertrophy classification based on
concentricity, mass, and volume quantification. Front Cardiovasc Med
2021;<i>https://doi.org/10.3389/fcvm.2021.667984</i></li><li>Nadarajah R, Patel PA, Tayebjee MH. Is hypertensive left ventricular
hypertrophy a cause of sustained ventricular arrhythmias in humans? J
Human Hypertension 2021;35: 492-498.</li><li>Moore JC, Trager L, Anzia L, et al. Dofetilide for suppression of
atrial fibrillation in hypertrophic cardiomyopathy: A case series and
literature review. Pacing Clin Electrophysiol 2018;41: 396-401.</li><li>Hohnloser SH, Crijns, HJ, van Eickels M, et al. Effect of dronedarone
on cardiovascular events in atrial fibrillation. N Engl J Med.
2009;360: 668-678.</li><li>Reiffel JA, Naccarelli GV. Antiarrhythmic drug therapy for atrial
fibrillation. Are the guidelines guiding clinical practice? Clin
Cardiol 2006; 29: 97-102.</li><li>Naccarelli GV. Antiarrhythmic drugs for atrial fibrillation in the
real world. J Am Coll Cardiol EP 2019:5(2): 242-243.</li><li>Pedersen OD, Bagger H, Keller N, Marchant B, Køber L, Torp-Pedersen C.
Efficacy of dofetilide in the treatment of atrial fibrillation-flutter
in patients with reduced left ventricular function: a
Danish-investigations of arrhythmia and mortality on dofetilide
(Diamond) substudy. Circulation. 2001 Jul 17;104(3): 292-296.</li><li>Shantha G, Chugh A, Crawford T, et al. Comparative efficacy of
dofetilide versus amiodarone in patients with atrial fibrillation. J
Am Coll Cardiol: EP 2021;7: 642-648.</li></ol>